{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:05:39Z","timestamp":1760299539420},"reference-count":24,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,2,1]]},"abstract":"<jats:p> PURPOSE: To determine the efficacy of mantle radiation therapy alone in selected patients with early-stage Hodgkin\u2019s disease. <\/jats:p><jats:p> PATIENTS AND METHODS: Between October 1988 and June 2000, 87 selected patients with pathologic stage (PS) IA to IIA or clinical stage (CS) IA Hodgkin\u2019s disease were entered onto a single-arm prospective trial of treatment with mantle irradiation alone. Eighty-three of 87 patients had \u2265 1 year of follow-up after completion of mantle irradiation and were included for analysis in this study. Thirty-seven patients had PS IA, 40 had PS IIA, and six had CS IA disease. Histologic distribution was as follows: nodular sclerosis (n = 64), lymphocyte predominant (n = 15), mixed cellularity (n = 3), and unclassified (n = 1). Median follow-up time was 61 months. <\/jats:p><jats:p> RESULTS: The 5-year actuarial rates of freedom from treatment failure (FFTF) and overall survival were 86% and 100%, respectively. Eleven of 83 patients relapsed at a median time of 27 months. Nine of the 11 relapses contained at least a component below the diaphragm. All 11 patients who developed recurrent disease were alive without evidence of Hodgkin\u2019s disease at the time of last follow-up. The 5-year FFTF in the 43 stage I patients was 92% compared with 78% in the 40 stage II patients (P = .04). Significant differences in FFTF were not seen by histology (P = .26) or by European Organization for Research and Treatment of Cancer H-5F eligibility (P = .25). <\/jats:p><jats:p> CONCLUSION: Mantle irradiation alone in selected patients with early-stage Hodgkin\u2019s disease is associated with disease control rates comparable to those seen with extended field irradiation. The FFTF is especially favorable among stage I patients. <\/jats:p>","DOI":"10.1200\/jco.2001.19.3.736","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T08:12:12Z","timestamp":1487923932000},"page":"736-741","source":"Crossref","is-referenced-by-count":12,"title":["Results of a Prospective Trial of Mantle Irradiation Alone for Selected Patients With Early-Stage Hodgkin\u2019s Disease"],"prefix":"10.1200","volume":"19","author":[{"given":"Kendall H.","family":"Backstrand","sequence":"first","affiliation":[{"name":"From the Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Department of Radiation Oncology, Duke University, Durham, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea K.","family":"Ng","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Department of Radiation Oncology, Duke University, Durham, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald W.","family":"Takvorian","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Department of Radiation Oncology, Duke University, Durham, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen L.","family":"Jones","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Department of Radiation Oncology, Duke University, Durham, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Department of Radiation Oncology, Duke University, Durham, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly J.","family":"Molnar-Griffin","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Department of Radiation Oncology, Duke University, Durham, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Silver","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Department of Radiation Oncology, Duke University, Durham, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy J.","family":"Tarbell","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Department of Radiation Oncology, Duke University, Durham, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Mauch","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Department of Radiation Oncology, Duke University, Durham, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-084198","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.285"},{"key":"R2-084198","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(96)80013-0"},{"key":"R3-084198","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.947"},{"key":"R4-084198","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.1.47.47"},{"key":"R5-084198","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198512000-00003"},{"key":"R6-084198","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.19"},{"key":"R7-084198","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/3.suppl_5.117"},{"key":"R8-084198","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19881001)62:7<1364::AID-CNCR2820620721>3.0.CO;2-T"},{"key":"R9-084198","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90222-4"},{"key":"R10-084198","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.3.378"},{"key":"R11-084198","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930415)71:8<2613::AID-CNCR2820710828>3.0.CO;2-T"},{"key":"R13-084198","unstructured":"Hays  DM,   Ternberg  JL,   Chen  TT,  et al:  Complications related to 234 staging laparotomies performed in the Intergroup Hodgkin\u2019s Disease in Childhood study.   Surgery 96:  471,1984-478,"},{"key":"R14-084198","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3468(86)80419-5"},{"key":"R15-084198","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930260212"},{"key":"R16-084198","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.1.256"},{"key":"R17-084198","doi-asserted-by":"crossref","unstructured":"Molrine  D,   George  S,   Tarbell  N,  et al:  Antibody responses to polysaccharide and polysaccharide-conjugate vaccines following treatment for Hodgkin\u2019s disease.   Ann Intern Med 123:  824,1995-828,","DOI":"10.7326\/0003-4819-123-11-199512010-00003"},{"key":"R18-084198","doi-asserted-by":"crossref","unstructured":"Grimfors  G,   Soderquist  M,   Holar  G,  et al:  A longitudinal study of class and subclass of antibody response to pneumococcal vaccination in splenectomized individuals with special reference to patients with Hodgkin\u2019s disease.   Eur J Haematol 45:  101,1990-108,","DOI":"10.1111\/j.1600-0609.1990.tb00426.x"},{"key":"R19-084198","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-104-4-467"},{"key":"R20-084198","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.2.239"},{"key":"R22-084198","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.3.393"},{"key":"R23-084198","doi-asserted-by":"crossref","unstructured":"Liao  Z,   Ha  C,   Vlachaki  M,  et al:  Mantle irradiation alone for pathologic stage I and II Hodgkin\u2019s disease:   Long-term follow-up and patterns of failure.   Proc Am Soc Ther Radiol Oncol 45:  216,1999  (abstr, suppl 3)","DOI":"10.1016\/S0360-3016(99)90152-9"},{"key":"R24-084198","doi-asserted-by":"crossref","unstructured":"Noordijk  E,   Carde  P,   Hagenbeek  A,  et al:  Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin\u2019s disease. Six-year results of the EORTC-GPMC controlled clinical trials \u2019H7-VF\u2019, \u2019H7-F\u2019 and \u2019H7-U\u2019.   Proc Am Soc Ther Radiol Oncol 39:  173,1997  (abstr, suppl 2)","DOI":"10.1016\/S0360-3016(97)80635-9"},{"key":"R25-084198","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.1.81"},{"key":"R26-084198","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.2.257"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.3.736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:48:51Z","timestamp":1653515331000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.3.736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2,1]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,2,1]]}},"alternative-id":["10.1200\/JCO.2001.19.3.736"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.3.736","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2,1]]}}}